What Does Denali Therapeutics Do?

Total employees511
HeadquartersSouth San Francisco
Founded2015

Denali Therapeutics Inc. is a biopharmaceutical company dedicated to developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage diseases. Their scientific approach is rooted in an understanding of disease biology and a commitment to rigorous therapeutic development. Denali focuses on conditions such as Alzheimer's disease, Parkinson's disease, ALS, and Hunter syndrome (MPS II).

Where Is Denali Therapeutics's Headquarters?

HQ Function

The headquarters serves as the central hub for research and development, clinical operations, corporate administration, and strategic decision-making.

Notable Features:

State-of-the-art laboratory facilities for drug discovery and development, modern office spaces designed for collaboration. Located in a biotech campus environment.

Work Culture:

Denali fosters a science-driven, innovative, and collaborative work culture. Employees are typically passionate about tackling challenging neurodegenerative diseases and are encouraged to pursue cutting-edge research.

HQ Significance:

The South San Francisco location places Denali within a rich ecosystem of talent, research institutions, and venture capital, crucial for a biotech company focused on innovation and growth.

Values Reflected in HQ: The headquarters reflects Denali's commitment to scientific excellence, innovation, and a focused approach to developing transformative therapies.

Location:

Denali Therapeutics primarily operates from its headquarters in South San Francisco, California, which houses its core research, development, and corporate functions. They also maintain an international presence, notably with an office in Zurich, Switzerland (Denali Therapeutics International GmbH), to support global clinical trials, regulatory interactions, and potential commercial activities outside the United States. Their collaborations and clinical trial sites extend their operational reach globally.

Street Address:

161 Oyster Point Blvd

City:

South San Francisco

State/Province:

California

Country:

USA

Where Else Does Denali Therapeutics Operate Around the World?

Zurich, Switzerland

Address: Denali Therapeutics International GmbH, Hardturmstrasse 161, 8005 Zurich, Switzerland

To expand Denali's global reach, manage international clinical studies, and engage with European regulatory bodies and partners.

Buying Intent Signals for Denali Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Denali Therapeutics? Meet the Executive Team

As of April 2025, Denali Therapeutics' leadership includes:

Ryan Watts, Ph.D. - Chief Executive Officer & Director
Alexander Schuth - Chief Operating Officer
Carole Ho, M.D. - Chief Medical Officer and Head of Development
Joseph M. Lewcock, Ph.D. - Chief Scientific Officer
Erik Harris - Chief Commercial Officer
Steve E. Krognes - Chief Financial Officer
Katie Peng - Chief People Officer
Kimberly L. Smith, M.D., Ph.D. - Chief Development Officer, Late Stage
Anand Mehra, M.D. - Chief Medical Officer, Head of Early Clinical Development

Who's Investing in Denali Therapeutics?

Denali Therapeutics has been backed by several prominent investors over the years, including:

ARCH Venture Partners
F-Prime Capital
Flagship Pioneering
Baillie Gifford
Casdin Capital
The Alaska Permanent Fund
Invus
CPP Investments
SoftBank Vision Fund (historically, may have divested)

What Leadership Changes Has Denali Therapeutics Seen Recently?

Hire2
Exits1

Over the past 12-18 months, Denali has seen some strategic executive appointments and transitions to strengthen its leadership in development and commercialization phases. Notable changes include appointments in late-stage development and commercial roles, reflecting the company's pipeline maturation.

Departures

Gilbert J. Choi, Ph.D., Gilbert J. Choi, Ph.D., departed from his role as Chief Business Officer.

New Appointments:

Anand Mehra, M.D., Dr. Anand Mehra joined Denali Therapeutics as Chief Medical Officer, Head of Early Clinical Development.
Kimberly L. Smith, M.D., Ph.D., Dr. Kimberly L. Smith was appointed Chief Development Officer, Late Stage, having previously served in other development leadership roles at Denali.

What Technology (Tech Stack) Is Used byDenali Therapeutics?

Discover the tools Denali Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Denali Therapeutics Email Formats and Examples

Denali Therapeutics primarily uses the email format combining the first initial and last name of the employee, followed by @denalitherapeutics.com. Variations might exist but this is the most common structure.

[first_initial][last]@denalitherapeutics.com

Format

jdoe@denalitherapeutics.com

Example

85%

Success rate

What's the Latest News About Denali Therapeutics?

Denali Therapeutics Press ReleaseMay 21, 2024

Denali Therapeutics Announces Positive Clinical Data for TVI™-Enabled DNL126 (SAR443820) in Patients with Sanfilippo Syndrome Type A (MPS IIIA) from a Phase 1/2 Study

Denali announced positive interim data from a Phase 1/2 study of DNL126 (SAR443820), an investigational enzyme replacement therapy, showing significant biomarker reductions and safety in Sanfilippo Syndrome Type A patients....more

Denali Therapeutics Press ReleaseMay 7, 2024

Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Denali reported its Q1 2024 financial results, highlighting progress in its clinical programs, including advancements in Parkinson's, ALS, and MPS II programs, and a strong financial position....more

Denali Therapeutics Press ReleaseApril 2, 2024

Denali Therapeutics Announces First Participant Dosed in Phase 2b Study of Tividenofusp Alfa (DNL310) in MPS II (Hunter Syndrome)

Denali announced the dosing of the first participant in a global Phase 2b study of tividenofusp alfa (DNL310) for MPS II (Hunter syndrome), aiming to further evaluate its efficacy and safety....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Denali Therapeutics, are just a search away.